Katherine G. Finegan

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.

Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition.

Journal: Cancer research communications
Published: December 05, 2022

SAR of Novel 3-Arylisoquinolinones: meta-Substitution on the Aryl Ring Dramatically Enhances Antiproliferative Activity through Binding to Microtubules.

SAR of Novel 3-Arylisoquinolinones: meta-Substitution on the Aryl Ring Dramatically Enhances Antiproliferative Activity through Binding to Microtubules.

Journal: Journal of medicinal chemistry
Published: March 15, 2022

Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma.

Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma.

Journal: Cancers
Published: January 29, 2021

The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.

The extracellular-regulated protein kinase 5 (ERK5) enhances metastatic burden in triple-negative breast cancer through focal adhesion protein kinase (FAK)-mediated regulation of cell adhesion.

Journal: Oncogene
Published: April 21, 2020

Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer.

Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer.

Journal: Oncogene
Published: March 17, 2020

Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis.

Extracellular-Regulated Protein Kinase 5-Mediated Control of p21 Expression Promotes Macrophage Proliferation Associated with Tumor Growth and Metastasis.

Journal: Cancer research
Published: August 05, 2019

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.

Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin.

Journal: British journal of cancer
Published: June 08, 2019

Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.

Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 07, 2018

Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models.

Oxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer Models.

Journal: Cancer research
Published: July 30, 2015

ERK5 is a critical mediator of inflammation-driven cancer.

ERK5 is a critical mediator of inflammation-driven cancer.

Journal: Cancer research
Published: February 05, 2015

Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma.

Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma.

Journal: Cancer research
Published: April 10, 2014

The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs).

The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs).

Journal: Cellular signalling
Published: May 21, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026